Financial Performance - The company reported a net loss of $28 million for 2025, an increase of $17 million from the previous year, attributed to higher R&D, G&A, and interest expenses[8] - Total revenue for 2024 was $248,357, with no revenue reported for 2025[20] - Operating expenses increased significantly to $25,196,475 in 2025 from $10,601,899 in 2024, representing a 137.5% increase[20] - The net loss for 2025 was $28,016,641, compared to a net loss of $11,485,410 in 2024, indicating a 144.5% increase in losses year-over-year[20] - Loss per common share for 2025 was $0.39, up from $0.19 in 2024, reflecting a 105.3% increase in loss per share[20] - Comprehensive loss for 2025 was $27,147,924, compared to $11,089,885 in 2024, indicating a 144.5% increase[20] Cash and Investments - As of December 31, 2025, Terrestrial Energy held approximately $298 million in cash and short-term investments, a significant increase from $3.29 million in 2024[8] - Cash flows from investing activities totaled $200,638,289 in 2025, primarily due to the purchase of short-term investments amounting to $199,496,832[24] - Cash and cash equivalents at the end of 2025 were $97,164,391, a significant increase from $3,021,795 at the beginning of the year[24] - The company raised $311,394,447 from financing activities in 2025, a substantial increase compared to $7,254,268 in 2024[24] Expenses Breakdown - Research and development costs rose to $9,767,996 in 2025, compared to $5,176,932 in 2024, marking an increase of 88.5%[20] - General and administrative expenses surged to $14,266,775 in 2025 from $4,168,576 in 2024, a 242.5% increase[20] - Interest expense for 2025 was $3,900,997, compared to $1,223,929 in 2024, which is a 219.5% increase[20] - Stock-based compensation increased to $3,103,702 in 2025 from $670,243 in 2024, indicating a focus on incentivizing employees[24] Strategic Initiatives - Terrestrial Energy completed a business combination, raising approximately $292 million in gross proceeds, and began trading on Nasdaq under the ticker symbol IMSR[1] - The U.S. Nuclear Regulatory Commission accepted the IMSR Principal Design Criteria, marking a key step in licensing readiness for IMSR plant construction[3] - Terrestrial Energy received two "OTA" awards from the U.S. Department of Energy, supporting the TETRA project and the Fuel Line Assembly project, which are crucial for IMSR plant licensing and operation[3] - The company expanded its commercial reach through collaboration with Ameresco, enhancing its ability to execute IMSR plant projects across the U.S.[3] - Texas A&M University selected Terrestrial Energy to site a full-sized commercial IMSR Plant at its RELLIS campus, positioning it among the first commercial Generation IV reactor deployments[3] - The company is in the concluding phase of its reactor graphite irradiation and supplier selection program, essential for IMSR plant licensing and operation[3] Shareholder Information - As of December 31, 2025, Terrestrial Energy had 105.8 million shares issued and outstanding, including approximately 81.8 million common shares[8] - The weighted-average shares of common shares outstanding increased to 71,646,985 in 2025 from 60,414,175 in 2024, a growth of 18.6%[20] - The company recognized $29,787,900 from the conversion of convertible notes to common shares, indicating a strategic move to strengthen equity[24] - Proceeds from the issuance of Series A-1 preferred shares amounted to $25,797,201, contributing to the financing activities[24] - The company incurred $22,305,729 in transaction costs related to merger and recapitalization activities, reflecting ongoing strategic initiatives[24] Currency and Exchange Rate Impact - The company reported a foreign currency translation adjustment loss of $260,731 in 2025, contrasting with a gain of $395,525 in 2024[20] - The effect of exchange rate changes on cash and cash equivalents resulted in a decrease of $140,650, highlighting potential currency risk[24] Future Outlook - The company plans to provide updates on expected 2026 milestones, including commercial, regulatory, and development progress during the earnings call[5]

Financial Performance - The company reported a net loss of $28 million for 2025, an increase of $17 million from the previous year, attributed to higher R&D, G&A, and interest expenses [8]. - Total revenue for 2024 was $248,357, with no revenue reported for 2025 [20]. - Operating expenses increased significantly to $25,196,475 in 2025 from $10,601,899 in 2024, representing a 137.5% increase [20]. - The net loss for 2025 was $28,016,641, compared to a net loss of $11,485,410 in 2024, indicating a 144.5% increase in losses year-over-year [20]. - Loss per common share for 2025 was $0.39, up from $0.19 in 2024, reflecting a 105.3% increase in loss per share [20]. - Comprehensive loss for 2025 was $27,147,924, compared to $11,089,885 in 2024, representing a 144.5% increase [20]. - The company reported a foreign exchange loss of $57,214 in 2025, contrasting with a gain of $617,357 in 2024 [20]. Cash and Investment Activities - As of December 31, 2025, Terrestrial Energy held approximately $298 million in cash and short-term investments, a significant increase from $3.29 million in 2024 [8]. - Net cash used in operating activities for 2025 was $16,472,912, up from $8,202,934 in 2024, reflecting higher operational expenditures [24]. - Total cash and cash equivalents at the end of 2025 reached $97,164,391, a substantial increase from $3,021,795 at the beginning of the year [24]. - Net cash used in investing activities was $200,638,289 in 2025, compared to $662,270 in 2024, highlighting increased investment activities [24]. - Net cash provided by financing activities amounted to $311,394,447 in 2025, a significant rise from $7,254,268 in 2024, driven by various financing efforts [24]. - Proceeds from the issuance of convertible notes totaled $9,335,000 in 2025, compared to $6,563,000 in 2024, indicating increased capital raising efforts [24]. - The company made purchases of intangible assets totaling $86,150 in 2025, compared to $54,404 in 2024, suggesting ongoing investment in intellectual property [24]. Research and Development - Research and development costs rose to $9,767,996 in 2025, compared to $5,176,932 in 2024, marking an increase of 88.5% [20]. - The company is in the concluding phase of its reactor graphite irradiation and supplier selection program, essential for IMSR plant licensing and operation [3]. Regulatory and Licensing Developments - The U.S. Nuclear Regulatory Commission accepted the IMSR Principal Design Criteria, marking a key step in licensing readiness for IMSR plant construction [3]. - Terrestrial Energy received two "OTA" awards from the U.S. Department of Energy, supporting the TETRA project and the Fuel Line Assembly project, which are crucial for IMSR plant licensing and operation [3]. - Texas A&M University selected Terrestrial Energy to site a full-sized commercial IMSR Plant at its RELLIS campus, positioning it among the first commercial Generation IV reactor deployments [3]. Shareholder Information - As of December 31, 2025, Terrestrial Energy had 105.8 million shares issued and outstanding, including approximately 81.8 million common shares [8]. - The weighted-average shares of common shares outstanding increased to 71,646,985 in 2025 from 60,414,175 in 2024, an increase of 18.5% [20]. Future Outlook - The company plans to provide updates on expected 2026 milestones, including commercial, regulatory, and development progress during the earnings call [5].

Financial Performance - Net loss attributable to common stockholders for the year ended December 31, 2025, was $26.6 million, or $1.67 per share, a decrease from a net loss of $37.8 million, or $5.65 per share, in 2024[7] - Total operating expenses for the year ended December 31, 2025, were $29.5 million, down from $32.1 million in 2024[17] - The change in fair value of the warrant liability resulted in other income of $2.0 million for the year ended December 31, 2025, compared to an expense of $5.8 million in 2024[16] Cash and Assets - As of March 30, 2026, the company reported unaudited cash, cash equivalents, and marketable securities totaling $54.9 million, providing a runway into 2027[8] - Total assets increased to $49.1 million as of December 31, 2025, from $31.7 million in 2024[15] - Stockholders' equity rose to $30.2 million as of December 31, 2025, compared to $7.4 million in 2024[15] Expenses - Research and Development (R&D) expenses decreased to $9.1 million for the year ended December 31, 2025, from $20.0 million in 2024, primarily due to reduced drug development and clinical trial costs[5] - General and Administrative (G&A) expenses increased to $20.4 million for the year ended December 31, 2025, compared to $12.1 million in 2024, driven by higher consulting and commercial launch preparation costs[6] - Total operating expenses for the year ended December 31, 2025, were $29.5 million, down from $32.1 million in 2024[17] Regulatory and Commercial Activities - The FDA accepted the resubmission of the New Drug Application (NDA) for oxylanthanum carbonate (OLC), with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026[10] - The company is preparing for a potential commercial launch of OLC in the third quarter of 2026, with ongoing commercial readiness activities[9]

Corporate Structure and Financial Transactions - ECARX Holdings is a Cayman Islands holding company, and investors are acquiring interest in this holding company rather than in any operating company[26]. - In 2023, ECARX Technology Limited repaid US$119.3 million to ECARX Holdings, while ECARX Holdings made advances totaling US$115.0 million to ECARX Group Limited and US$2.7 million to ECARX Technology Limited[41]. - In 2024, ECARX Holdings made advances of US$12.5 million to ECARX Group Limited and US$1.0 million to ECARX Technology Limited[41]. - In 2025, ECARX Holdings made advances totaling US$42.0 million to ECARX Group Limited and US$62.4 million to ECARX Technology Limited[41]. - The restructuring in 2022 terminated the VIE corporate structure, which had been subject to increased regulatory scrutiny, and currently, there are no VIEs in China[28]. - As of the date of the annual report, none of the mainland China subsidiaries has been subject to penalties for failing to obtain necessary business licenses or permits[32]. - The company has not declared or paid dividends and does not intend to do so in the near future[43]. - Restrictions exist on inter-company fund transfers and foreign exchange control affecting dividend payments from mainland China subsidiaries[44]. - Current regulations allow mainland China subsidiaries to pay dividends only from accumulated after-tax profits, which may limit cash flow to the parent company[196]. - As of December 31, 2025, many mainland China subsidiaries reported accumulated losses, affecting their ability to pay dividends[197]. - Limitations on dividend payments from mainland China subsidiaries could adversely impact the company's ability to grow and invest[198]. - The withholding tax rate on dividends from mainland China subsidiaries to foreign enterprises is currently 10%, potentially reduced to 5% if certain conditions are met[221]. - As of December 31, 2025, most subsidiaries in mainland China reported accumulated losses, resulting in no retained earnings available for offshore distribution[221]. - The company intends to reinvest any earnings generated from mainland China subsidiaries for business operations and expansion in China[221]. Regulatory Environment and Compliance - The PCAOB has not issued any new determination that it is unable to inspect or investigate registered public accounting firms in any jurisdiction, which is crucial for compliance with the Holding Foreign Companies Accountable Act[30]. - The PRC government has intensified control over overseas capital raising by China-based issuers, which may affect future operations[33]. - As of the date of the report, ECARX Holdings does not expect to be identified as a Commission-Identified Issuer under the HFCAA after filing the annual report for the fiscal year ended December 31, 2025[31]. - The company is subject to evolving cybersecurity and data protection laws, with potential breaches leading to reputational damage and legal liabilities[108]. - The company has implemented strict information security policies, but risks remain due to the evolving nature of cyber threats[110]. - The company may face increased compliance costs and obligations due to new regulations on data security and privacy in China[112]. - The company is subject to complex regulatory standards in the U.S. and Europe, including the GDPR, which imposes additional obligations regarding personal data handling[117]. - The company has incurred significant expenses to comply with privacy and data protection standards, which may increase due to changes in laws and regulations[118]. - The PRC government may impose restrictions on foreign investments and overseas offerings, affecting the company's ability to operate and raise capital[171]. - The company must comply with confidentiality and archives management requirements during overseas offerings, which could complicate operations[176]. - Any changes in regulatory requirements could significantly impact the company's ability to conduct business and the value of its securities[181]. - The PCAOB was historically unable to inspect auditors in mainland China, impacting investor confidence in audit quality[182]. - As of December 15, 2022, the PCAOB removed mainland China and Hong Kong from the list of jurisdictions it cannot fully inspect[184]. - If the PCAOB loses access to inspect auditors in mainland China again, the company's securities may be prohibited from trading in the U.S. under the HFCAA[183]. - The SEC may prohibit trading of the company's securities if audit reports are issued by firms not inspected by the PCAOB for two consecutive years[183]. - Regulatory scrutiny from the SEC may increase compliance costs and complicate future securities offerings for companies with substantial operations in China[187]. - M&A activities in mainland China are subject to complex regulations, potentially hindering growth through acquisitions[188]. - The 2019 PRC Foreign Investment Law introduces uncertainties regarding foreign investment regulations and compliance requirements[190]. - The evolving legal system in China presents uncertainties that could limit legal protections and impact the company's operations and reputation[168]. - New regulations regarding overseas offerings and listings by mainland China-based companies may impose additional compliance requirements[174]. - The company may face significant uncertainties regarding the interpretation and implementation of the Overseas Listing Filing Rules and data security regulations[178]. - Failure to obtain necessary approvals or complete required filings could result in regulatory sanctions, including fines and operational restrictions[180]. - The company has not been involved in any cybersecurity reviews or received inquiries from PRC authorities as of the report date[176]. Financial Performance and Risks - The company has experienced negative net cash flows from operations in the past and has not been profitable, raising concerns about its ability to continue as a going concern[51]. - The company incurred net losses of US$143.9 million, US$137.8 million, and US$68.9 million in 2023, 2024, and 2025, respectively, and has not been profitable since inception[76]. - Negative cash flows from operating activities were US$172.4 million, US$60.0 million, and US$94.4 million in 2023, 2024, and 2025, respectively[76]. - The company has a net current liability of US$339.8 million as of December 31, 2025[76]. - The automotive intelligence industry is highly competitive, and the company faces significant challenges in a fast-developing market[51]. - The demand for the company's products is closely tied to automobile sales and production, which can be cyclical and influenced by various economic factors[62]. - Supply chain disruptions, particularly in semiconductor manufacturing, could materially affect production and profitability[67]. - The company is investing significantly in research and development to advance its automotive intelligence technologies, but market acceptance remains uncertain[60]. - The automotive intelligence market is expected to become more competitive, with increased demand for automotive intelligence technologies and ongoing industry consolidation[73]. - The company faces risks associated with international operations, including increased regulatory risks and local competition[83]. - The company relies on a concentrated customer base, particularly Geely Holding, which poses risks if key customer relationships are disrupted[79]. - The company may need to seek additional equity or debt financing to support its operations, which could dilute shareholders or impose operational restrictions[92]. - The company may face challenges in obtaining necessary financing due to market conditions, which could lead to reduced spending or changes in corporate structure[93]. - Future capital needs may require the issuance of additional equity or debt securities, potentially diluting shareholder interests and increasing debt service obligations[94]. - The company has completed several acquisitions, including controlling interests in JICA Intelligent and Suzhou Photon-Matrix, and plans to continue pursuing strategic investments to enhance its product offerings[96]. - The company is exposed to risks from warranty claims and product liabilities, which could adversely affect profitability and financial position[97]. - Expansion or conversion of production facilities may encounter delays and cost overruns, impacting production capacity and financial results[102]. - Compliance with environmental laws and regulations may impose substantial costs and cause delays in building production facilities[105]. - The company relies heavily on consumer spending in China, with revenues significantly impacted by economic conditions domestically and globally[131]. - Economic slowdown in China could materially and adversely affect the company's business and financial condition[131]. - Heightened geopolitical tensions, particularly between the U.S. and China, may negatively impact trade, investments, and the company's operations[135]. - The U.S. has imposed higher tariffs on certain products imported from China, which could adversely affect the company's sales and financial results[136]. - Ongoing geopolitical conflicts, such as those in the Red Sea and Ukraine, could disrupt global economic activities and supply chains, adversely affecting the company's operations[144]. - The company is vulnerable to natural disasters and other calamities, which could disrupt operations and adversely affect financial results[146]. - The company may incur substantial costs defending against intellectual property infringement claims, which could materially affect business operations[151]. - The company relies on information technology systems for daily operations, and disruptions could lead to significant costs and impact financial condition[160]. - The company has not experienced any material interruptions due to cyber-attacks or security breaches to date, but risks remain[162]. - The company may face claims related to open-source software usage, which could result in significant legal costs and impact proprietary software distribution[163]. Human Resources and Labor Costs - Labor costs in China are expected to increase, impacting profitability unless passed on to service payers[201]. - Stricter regulatory requirements for labor contracts and employee benefits may adversely affect business operations[202]. - The company relies heavily on its executive officers and key employees, and losing their services could severely disrupt operations and financial performance[124]. Intellectual Property and Technology - The company has 779 registered patents and 797 pending patent applications globally as of December 31, 2025[156]. - The company's ability to protect its intellectual property is critical, and unauthorized use by third parties could harm competitive position and revenues[154]. - The company's management concluded that internal control over financial reporting was effective as of December 31, 2025[149]. Brand and Reputation - The company's brand and reputation are vulnerable to negative publicity, which could harm its business and financial condition[128]. - Non-compliance with anti-corruption and anti-bribery laws could lead to severe penalties and adversely affect the company's reputation and financial condition[119]. - The company has limited insurance coverage, exposing it to significant costs and potential business disruptions[123].

Funding and Government Support - The U.S. government is expected to provide $1.6 billion in funding under the CHIPS Act to accelerate the establishment of a secure domestic supply chain for rare earths[34] - The implementation of DFARS 225.7018 will prohibit the Department of War from acquiring certain magnets produced in China, highlighting the need for compliant domestic supply chains[57] - The company is subject to agreements with government entities that provide incentives, which if not complied with, could negatively impact business operations[182] Project Development and Production Plans - The Accelerated Mining Plan anticipates the start of commercial production at Round Top in late 2028, leveraging one of North America's richest heavy rare earth deposits[34] - The planned production timeline for the Round Top Mountain project has been accelerated, targeting commercial production by late 2028, two years earlier than previously planned[73] - The Round Top Project, which includes land and water rights, is a joint venture where the company holds an 81.3% interest, aiming to streamline operations and enhance economic benefits[48] - The proposed TMRC Merger Agreement aims to secure 100% economic interest in the Round Top Project, enhancing operational efficiency[50] - The Colorado research and development facility is expected to become one of the largest solvent extraction demo facilities in the U.S., with over 500 planned mixer/settlers[76] Acquisitions and Strategic Relationships - The acquisition of Less Common Metals is expected to enhance industry relationships and improve control over the value chain, with plans to expand metal making capabilities to 3,750 metric tons per year in France[34] - Less Common Metals has established relationships with European defense and industrial customers, positioning itself to meet DFARS-compliant material requirements ahead of the January 2027 prohibition on Chinese-origin REE magnets in U.S. weapons systems[87] - The success of the LCM Acquisition relies on retaining existing customers and suppliers, as well as building new relationships[202] Production Capacity and Technology - The Stillwater Facility has successfully commissioned Phase 1a of sintered NdFeB permanent magnet block production, with customer orders expected to begin in Q2 2026[40] - The Stillwater Facility's Phase 1a is expected to produce approximately 600 MTPA of sintered NdFeB permanent magnet blocks at full capacity, with Phase 1b anticipated to match this output[89] - The company is developing a fully integrated mine-to-magnet platform essential for various industrial sectors, including aerospace and defense[50] - Advanced grain-boundary-diffusion technology enhances magnetic performance while reducing the need for both LREEs and HREEs, supporting sustainable solutions[92] Market Dynamics and Competition - Heavy rare earth elements are critical for U.S. defense and advanced technology platforms, with China controlling approximately 99% of global processing[54] - The company faces significant competition from China, which controls a substantial majority of the global rare earth magnet production and benefits from government support[97] - Domestically, competition includes MP Materials, Noveon Magnetics, and VACUUMSCHMELZE, with emerging competitors like KSM Metals also entering the market[98] - The market for neo magnets is influenced by global supply and demand dynamics, with China dominating production and regulatory factors affecting pricing[167] Financial Performance and Risks - The company incurred a net loss of $298.5 million for the year ended December 31, 2025, with an accumulated deficit of $387.4 million as of the same date[157] - The company's revenues for 2025 were solely derived from the Less Common Metals business, with no revenue generated from neo magnet manufacturing or mineral production[157] - The company anticipates needing additional capital to fund ongoing operations and complete the Stillwater Facility, with potential reliance on equity or debt financing[172] - The company does not currently have any contractually committed customers for neo magnets, which could negatively impact revenue generation[160] Environmental and Regulatory Compliance - Environmental regulations significantly impact operations, with ongoing expenditures expected for compliance and sustainability initiatives[107] - The company is subject to various environmental, health, and safety regulations in the U.K. and EU, which may impose significant compliance costs and operational constraints[122][123] - The mining industry is particularly exposed to stringent regulations regarding greenhouse gas emissions, which may materially impact the company's financial condition and operational prospects[230] - Compliance with anti-corruption and anti-bribery laws is critical, as failure to do so may result in significant sanctions, including criminal fines and civil penalties[227] Research and Development - The R&D Program focuses on developing various NdFeB grades, including high-temperature grades critical for defense applications, which can maintain performance above 150°C[91] - Research and development programs are critical for establishing commercially viable extraction and manufacturing operations, but success is not guaranteed[150] Operational Challenges - The company faces risks from potential economic contractions that could lead to lower prices for neo magnets, impacting revenues and development funds[166] - Disruptions in power supply at projects could delay operations and increase costs, adversely affecting revenue and customer relationships[177] - Diminished access to water could adversely affect operations, especially with increased water requirements post-Round Top Project completion[181] - The company must implement adequate health and safety systems to mitigate risks associated with workplace hazards, which could have a material effect on its reputation and financial condition[224]

Financial Performance - The company incurred net losses of $106.2 million and $86.9 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $480.4 million as of December 31, 2025[216]. - The company has not generated any revenue from product sales to date and does not expect to do so in the foreseeable future[216]. - The company will require substantial additional capital to finance its operations and may need to pursue equity or debt financings, which could dilute existing stockholders[222]. - The company does not anticipate paying any cash dividends on its capital stock in the foreseeable future, with capital appreciation being the sole source of gain for stockholders[404]. - Future sales of common stock could result in substantial dilution for existing stockholders, with a registration statement filed for the offering of up to $75 million in common stock[414]. - Quarterly operating results may fluctuate significantly, influenced by various factors including clinical trial results and collaboration arrangements[406]. Going Concern and Capital Requirements - As of December 31, 2025, the company had cash and cash equivalents and marketable securities of $144.2 million, which are insufficient to fund bel-sar through regulatory approval[221]. - The company faces substantial doubt about its ability to continue as a going concern for at least twelve months following the filing of the Annual Report[221]. - The company has no committed external source of funds and may face challenges in obtaining additional financing on acceptable terms[222]. - The company’s auditors have issued a "going concern" audit opinion, indicating substantial doubt about its ability to continue as an ongoing business[224]. - If the company fails to raise capital as needed, it may have to delay or eliminate clinical trials and research and development programs[223]. Research and Development - The company anticipates significant increases in research and development expenses as it continues clinical development for bel-sar and other product candidates[216]. - The success of the company heavily relies on the development and commercialization of its only product candidate, bel-sar, which is focused on multiple oncology indications[232]. - The company has initiated a global Phase 3 trial for bel-sar but has not yet completed pivotal clinical trials necessary for regulatory approval[244]. - The company expects to focus its resources on the development of bel-sar in the near term, which may limit its commercial opportunities if additional product candidates are not developed[245]. - The lengthy and unpredictable regulatory approval process may result in delays or failure to market product candidates, significantly harming the company's business prospects[238]. Regulatory Risks - Regulatory approval for bel-sar is subject to comprehensive regulation by the FDA and foreign authorities, and failure to obtain such approval would materially impair revenue generation[236]. - The approval process for bel-sar may be complicated due to its requirement for a drug delivery device and activation by a laser, increasing regulatory risks[247]. - The company must establish commercially viable supply and manufacturing relationships to support clinical development and market demand for bel-sar if approved[230]. - Regulatory authorities may require additional warnings or limitations on product labeling if undesirable side effects are identified post-approval[264]. - The FDA may require a Risk Evaluation and Mitigation Strategy (REMS) for approved product candidates, which could include distribution restrictions[273]. Clinical Trials and Market Acceptance - The company faces risks related to the commercial acceptance of bel-sar by patients, the medical community, and third-party payors, which are critical for revenue generation[235]. - Delays in patient enrollment for clinical trials could hinder the receipt of necessary regulatory approvals[249]. - The company may face challenges in recruiting sufficient eligible patients due to competition and perceived risks associated with product candidates[250]. - Conducting clinical trials outside the United States may not guarantee acceptance of data by the FDA or foreign regulatory authorities, potentially requiring additional trials[252]. - Adverse events or side effects identified during clinical trials could delay or prevent marketing approval and affect the product's market acceptance[262]. Intellectual Property and Legal Risks - The ability to protect proprietary rights is crucial for commercial success, with potential challenges from third-party patent claims[324]. - Legal disputes over intellectual property rights can be costly and may divert management resources, impacting business operations[329]. - The company may face potential patent infringement claims that could result in substantial costs and delays in product development and commercialization[342]. - Litigation related to patent rights is common in the biotechnology industry, which may hinder the company's ability to operate effectively[343]. - The complexity of patent laws and potential changes could affect the ability to protect intellectual property effectively[341]. Market and Competitive Landscape - The company faces intense competition from established pharmaceutical and biotechnology companies, which may have greater resources and capabilities[312]. - The market opportunity for bel-sar may be smaller than estimated, adversely affecting revenue and profitability[315]. - Regulatory approval of product candidates may be limited by the availability and pricing of competitors' products, affecting demand[313]. - The company may encounter challenges in obtaining adequate coverage and reimbursement from third-party payors, impacting product acceptance[314]. Compliance and Regulatory Environment - Compliance with healthcare regulatory laws is critical, as violations could lead to significant penalties and operational disruptions[319]. - Legislative and regulatory changes in the healthcare system may adversely affect the approval and profitability of current and future product candidates[320]. - Increased state-level initiatives in the U.S. are aimed at controlling pharmaceutical pricing, which could pressure product demand and pricing[321]. - Future healthcare reforms may limit government payments for healthcare products, potentially reducing demand for product candidates[322]. Data Privacy and Cybersecurity - Cybersecurity incidents could disrupt product development programs and lead to unauthorized access to sensitive information, resulting in financial and reputational harm[364]. - The company may face significant costs related to compliance with evolving data privacy laws, including the California Consumer Privacy Act (CCPA) and other state regulations[373]. - Non-compliance with data protection laws could lead to government enforcement actions, private litigation, and increased operational costs[370]. - The GDPR imposes fines of up to €20 million or 4% of worldwide annual turnover for violations, which increases compliance burdens for the company[379]. Management and Operational Challenges - The potential loss of key management personnel could impair the company's business strategy and competitiveness[355]. - The company anticipates significant growth in operations, particularly in sales and marketing, which may strain management resources and disrupt operations[394]. - The company currently lacks marketing and sales organization and experience, which may hinder its ability to generate product revenue[308]. - Establishing an in-house marketing organization will require significant capital expenditures and management resources[308].

Financial Performance - The company reported a net loss of $324.2 million for the year ended December 31, 2025, compared to a net loss of $243.8 million for 2024, with an accumulated deficit of $920.5 million as of December 31, 2025[442]. - The company expects to continue incurring substantial losses as it advances its research and development efforts, with no immediate expectation of profitability[442]. - The company will require substantial additional capital to finance operations and achieve business objectives, with potential delays or reductions in research programs if capital is not raised[446]. - Adverse global economic conditions, including inflation and geopolitical events, could negatively impact the company's operations and financial performance[486]. - Changes in U.S. government policies, including tariffs and reductions in federal research funding, could adversely affect the company's business[487]. Product Development and Clinical Trials - The company is conducting a Phase 2/3 registrational trial for EIK1001 in combination with pembrolizumab for advanced melanoma and a Phase 2 trial for non-small cell lung cancer[439]. - EIK1001 is the most advanced product candidate, currently in a Phase 2/3 registrational trial for advanced melanoma and a Phase 2/3 trial for NSCLC[491]. - The company has not completed any pivotal clinical trials for its product candidates, which are primarily in preclinical or early-stage clinical development[491]. - The company faces high risks of failure in clinical development, with potential delays in obtaining regulatory approvals that could extend commercialization timelines by many years[492]. - The regulatory approval process is lengthy and unpredictable, with no product candidates having received approval to date, which could significantly harm the business[503]. Research and Development - The company has invested heavily in the development of its product candidates, which are still in preclinical or clinical development, and expects to continue this trend[454]. - The company has invested significantly in research and development to enhance its technology platform, which includes proprietary software, hardware, and datasets, but faces risks related to timely and cost-effective implementation of enhancements[462]. - The company relies on its technology platform to improve drug development speed and success probability, but there is uncertainty regarding its ability to identify clinically relevant biomarkers or additional product candidates[459]. Regulatory and Compliance Risks - The company must maintain compliance with various regulatory standards and may face significant penalties for noncompliance, which could impact its operations and reputation[471]. - The company is subject to numerous foreign regulatory requirements, which may differ significantly from U.S. regulations, adding complexity to the approval process[508]. - The company may face significant financial penalties if it or any future partner fails to comply with regulatory requirements related to product development and safety monitoring[534]. Intellectual Property Risks - The company faces risks related to intellectual property, including the potential inability to obtain sufficient patent protection for product candidates, which could allow competitors to develop similar products[573]. - The company has in-licensed certain patents related to EIK1001 but lacks composition of matter patents for EIK1001 as a sole active ingredient, limiting competitive protection[575]. - The company may face challenges in enforcing patent rights, which could result in loss of exclusivity or narrowed patent claims, adversely affecting its business prospects[581]. - The company may face various patent disputes that could adversely affect its exclusivity and patent claims, potentially leading to significant costs and operational impacts[587]. Collaboration and Partnerships - The company has entered into collaborations with several entities, including Seven and Eight Biotherapeutics and MSD International Business GmbH, to advance research and development activities[472]. - Collaborations are complex and may not lead to efficient development or commercialization, potentially requiring the company to raise additional capital[475]. - The company may need to enter collaborations or licensing arrangements, which could result in relinquishing valuable rights to its technologies or future revenue streams[453]. Market and Competitive Landscape - The company faces substantial competition from larger pharmaceutical and biopharmaceutical companies, which may hinder its ability to successfully develop and commercialize its products[542]. - Market acceptance of product candidates is uncertain and depends on factors such as safety, efficacy, cost, and competition, which could affect revenue generation[536]. - The company estimates that the market opportunities for its product candidates may be smaller than anticipated, with actual market growth subject to numerous uncertainties[539]. Operational Challenges - The company may encounter challenges in attracting and retaining qualified personnel due to intense competition in the biopharmaceutical sector, which could impede its business objectives[466]. - The company faces significant product liability risks during clinical trials, which could adversely affect its financial condition and operational results[470]. - Delays in participant enrollment or withdrawals from trials could compromise data quality and increase costs[497].

Financial Performance and Projections - The company has incurred significant losses since its inception in November 2019, with an accumulated deficit of $1,184.1 million as of December 31, 2025, and expects to continue incurring losses for the foreseeable future [138]. - The company has no products approved for commercial sale and has not generated any revenue from product sales, relying primarily on financing through common stock and convertible securities [138]. - The company anticipates substantial increases in expenses and operating losses as it expands research and development efforts, advances clinical candidates, and seeks regulatory approvals [139]. - The company must successfully identify, develop, and commercialize products to achieve profitability, which involves completing clinical trials and obtaining regulatory approvals [141]. - The company has not yet demonstrated the ability to complete late-stage clinical trials or commercialize products, which may impact its future success [149]. - The company expects to continue to expend significant resources for product development and may seek additional capital due to favorable market conditions, which could divert management from day-to-day activities [153]. Funding and Financial Obligations - The company has contingent obligations from acquisitions, including up to $365.0 million in milestone payments related to navacaprant and up to $450.0 million in sales-based milestones [144]. - Under its license agreements, the company is obligated to pay up to $720.0 million in commercial milestone payments to Amgen and $422.4 million to Vanderbilt University upon achieving certain milestones [145][146]. - The company may need to issue equity or incur debt to satisfy its payment obligations, which could dilute stockholder value and affect its financial position [147]. - The company raised aggregate net proceeds of $19.7 million and $13.7 million in 2025 and 2024, respectively, through sales of common stock under an ATM agreement [156]. - The company entered into a loan agreement with K2 HealthVentures LLC, which includes covenants that may limit its ability to incur additional debt [156]. Competition and Market Environment - The company operates in a highly competitive environment, facing risks related to drug development timelines and regulatory approvals that could adversely affect its business [142]. - The biotechnology industry is highly competitive, with significant risks from larger companies and rapid technological changes [180]. - The company faces intense competition for skilled personnel, particularly in Massachusetts and California, which may impact its ability to attract and retain key employees [173]. - The company is focused on acquiring and in-licensing assets and technologies to enhance its product pipeline and precision neuroscience tools [174]. Clinical Development and Regulatory Challenges - Clinical and preclinical drug development processes are lengthy and expensive, with uncertain outcomes that could delay regulatory approvals [194]. - The company must conduct extensive preclinical and clinical trials to demonstrate the safety and efficacy of its product candidates, which is a lengthy and costly process [195]. - Delays in clinical trials can arise from various factors, including difficulties in patient recruitment, regulatory approvals, and adherence to clinical protocols [198]. - The transition to the EU Clinical Trials Regulation (CTR) may impact the company's development plans, as it introduces a centralized application process for multi-center trials [201]. - The company faces risks associated with conducting clinical trials in foreign countries, including cultural differences and regulatory challenges [197]. - Adverse side effects identified during clinical trials could lead to delays in marketing approval or limit the commercial profile of approved products [208]. Regulatory Compliance and Risks - Regulatory approval processes are lengthy and unpredictable, and failure to obtain timely approval could significantly harm the business [232]. - The company has not previously submitted a New Drug Application (NDA) and lacks experience in this area, which could complicate the approval process [233]. - Non-compliance with regulatory requirements may lead to significant penalties, including civil or criminal penalties, and could adversely affect the company's value and operating results [241]. - Changes in FDA policies or additional government regulations may delay or prevent regulatory approval of product candidates, impacting profitability [242]. - The FDA actively enforces laws prohibiting off-label promotion, and violations could result in significant liability for the company [243]. Intellectual Property and Legal Risks - The company is party to various intellectual property license agreements, and any breach or termination could harm its ability to develop and commercialize product candidates [297]. - Future royalty obligations from licensed technologies may be significant, impacting profitability even if products are successfully developed [301]. - The ability to enforce patent rights depends on licensors, and failure to conduct necessary legal actions could adversely affect product development [304]. - The company may face challenges in maintaining existing intellectual property rights, which could lead to abandoning research programs or product candidates [302]. - The company may need to initiate costly litigation to defend its patent rights, which could divert resources from core business activities [333]. Operational and Supply Chain Risks - The company relies on third-party manufacturers for the production of product candidates, which increases the risk of supply disruptions and delays in clinical trials [285]. - The company does not have long-term supply agreements with manufacturers, making it vulnerable to unexpected supply losses [285]. - The company expects to continue relying on third-party manufacturers for commercial supply, which entails risks related to compliance with Good Manufacturing Practices (cGMP) and quality control [286]. - The company depends on third-party clinical research organizations (CROs) for conducting preclinical studies and clinical trials, which poses risks if these parties fail to meet obligations [292]. Data Privacy and Compliance Costs - The company faces potential liability related to the privacy of health information utilized in product development and clinical trials, with compliance costs expected to increase in the future [271]. - The company may incur substantial operational costs to comply with U.S. federal and state data privacy and security laws, which could lead to significant fines and penalties if compliance is not met [277]. - The General Data Protection Regulation (GDPR) imposes stringent operational requirements for processing personal data in the European Economic Area, with potential fines up to €20 million or 4% of global turnover for non-compliance [278]. - The California Consumer Privacy Act (CCPA) requires businesses to provide disclosures regarding personal information collection and may increase compliance costs and potential liability for the company [276].

Financial Performance - For the year ended December 31, 2025, the net loss was approximately $34.5 million, or $0.74 per share, compared to a net loss of $37.6 million, or $1.03 per share for 2024, representing a 8.5% improvement in loss per share [6]. - Long-term debt increased to $11.7 million in 2025 from $9.2 million in 2024, reflecting a rise of 27.4% [17]. - The accumulated deficit as of December 31, 2025, was $(216.6) million, compared to $(182.1) million in 2024, indicating an increase in the deficit of 18.9% [17]. Expenses - Research and development expenses decreased to $19.0 million in 2025 from $22.6 million in 2024, a reduction of $3.6 million, primarily due to lower manufacturing and personnel costs [7]. - General and administrative expenses for 2025 were $12.5 million, down from $13.8 million in 2024, reflecting a decrease of $1.3 million primarily due to reduced personnel costs [8]. - Total operating expenses for 2025 were $31.5 million, compared to $36.3 million in 2024, indicating a decrease of 13.5% [8]. Cash Position - The cash balance as of December 31, 2025, was $26.7 million, down from $41.7 million at the end of 2024 [10]. Clinical Trials and Research - The company amended the VERSATILE-003 Phase 3 clinical trial protocol to include progression-free survival (PFS) as an interim primary endpoint, potentially shortening trial duration and reducing costs [4]. - Early results from the NCI-led trial of PDS01ADC showed a median PFS of 9.6 months and a median PSA decline of 40% in patients with metastatic castration-resistant prostate cancer [4]. Intellectual Property - The company strengthened its intellectual property estate for PDS0101 with new patents granted in the U.S. and Japan, extending market protection into the 2040s [5].

Financial Performance - The net loss for the full year 2025 was $106.2 million, compared to a net loss of $86.9 million in 2024[17]. - The total operating loss for the full year 2025 was $112.8 million, compared to $96.1 million in 2024[20]. - General and administrative expenses decreased to $22.5 million for the full year 2025, down from $22.8 million in 2024, driven by reduced professional fees[17]. - Research and development expenses for the full year 2025 were $90.3 million, an increase from $73.3 million in 2024, primarily due to ongoing clinical trial costs[17]. - As of December 31, 2025, the company had cash and cash equivalents and marketable securities totaling $144.2 million, sufficient to fund operations into Q1 2027[17]. Clinical Trials and Developments - The ongoing Phase 3 CoMpass trial is expected to complete enrollment by mid-2026, with topline data anticipated in the second half of 2027[2]. - Initial three-month clinical data from the Phase 1b/2 NMIBC trial is expected in mid-2026[2]. - The ongoing Phase 2 trial for bel-sar in metastases to the choroid is on track to report early data in 2026, addressing a high unmet medical need[10]. - The company achieved 12-month stability for a new formulation designed for non-ocular solid tumors, starting with urologic oncology[8]. - The company has received FDA Fast Track designation for bel-sar in the treatment of early choroidal melanoma and metastases to the choroid[5].